BioSpace News Archive

Business

Agile Therapeutics Appoints Josephine Torrente to its Board of Directors

Agile Therapeutics, Inc., a women’s healthcare company, announced that Josephine Torrente has been appointed to the Company’s board of directors, as a Class II director, effective as of October 7, 2021.

October 8, 2021
·
4 min read
FDA

Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia

Enzyvant announced the U.S. Food and Drug Administration approval of RETHYMIC®, a one-time regenerative tissue-based therapy for immune reconstitution in pediatric patients with congenital athymia.

October 8, 2021
·
10 min read
Pharm Country

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 08, 2021

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to five new employees.

October 8, 2021
·
3 min read
Biotech Bay

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Oct 08, 2021

Rigel Pharmaceuticals, Inc. reported the grant of stock options to purchase an aggregate of 469,000 shares of common stock to 23 newly hired employees.

October 8, 2021
·
2 min read
FDA

FDA Approves Innovative Treatment for Pediatric Patients with Congenital Athymia

The U.S. Food and Drug Administration approved Rethymic for the treatment of pediatric patients with congenital athymia, a rare immune disorder. Rethymic is the first thymus tissue product approved in the U.S.

October 8, 2021
·
3 min read